Obermatt
See Similar Stocks →

Ilyang Pharmaceutical

KSC:007570 · KR7007570005
PharmaceuticalsSmall

360

30
Medium confidence — indicative
EV / EBIT7
Price / Owner Earnings21
Owner Earnings Yield84
Dividend Yield1
Price/Sales64
EV / Gross Profit62
Price/Book79
Return on Capital55
Cash Return on Capital82
Return on Equity80
EBIT Margin42
Gross Profitability59
Cash Conversion73
Accruals59
Owner Earnings Margin85
Sales growth43
Profit Growth99
Long-Term EPS Growth7
Reinvestment34
Price momentum9
Debt load37
Refinancing41
Debt Payback56
Liquidity16
Analyst ratings—
Expectations trend—
Market mood86
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Ilyang Pharmaceutical doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSE
Employees14
Websiteilyang.co.kr
ISINKR7007570005
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
DermatologyOphthalmologyVaccinesNeurologyPharmaceutical

Description

Analysis

Quality compounder

Ilyang Pharmaceutical Co.,Ltd earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is attractive. The owner-earnings multiple stands at 6.2×; owner earnings: the cash an owner could take out each year.

Growth is tepid; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
43
20232026

All-time high

43

Jun 2026

All-time low

8

Mar 2026

Average rank

27

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
64
—
—
72
Price/Earnings
74
—
—
53
Price/Book
79
—
—
52
Dividend Yield
1
—
—
31
Value (overall)
55
—
—
45

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Ilyang Pharmaceutical with its peers
Daewoong Pharmaceutical
KSC:069620
27
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Aprogen Biologics
KSC:003060
10
CountrySouth Korea
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
PharmGen Science
KSC:004720
74
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Reyon Pharmaceutical
KSC:102460
16
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Chongkundang Holdings
KSC:001630
56
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Il Dong Pharmaceutical
KSC:249420
53
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →